DIVISLAB
532488Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Submission of Scrutinizer''s report on 36th AGM resolutions.
Divis Laboratories Ltd is a leading Indian pharmaceutical company specializing in the manufacture of active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients. Headquartered in Hyderabad, the company operates large-scale manufacturing facilities in Andhra Pradesh and Telangana, with a global footprint spanning over 100 countries. Established in 1990, Divis is known for its strong chemistries, process innovation, and focus on custom synthesis and contract manufacturing for major pharmaceutical companies worldwide.
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Submission of Scrutinizer''s report on 36th AGM resolutions.
Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of 36th AGM - submission of AGM proceedings, voting results and Scrutinizer''s report.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Submission of transcript of Earnings Conference Call held on August 01, 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper clippings regarding unaudited financial results of the Company for the quarter ended June 30, 2026
Divis Laboratories Ltd
About
Divis Laboratories Ltd is a leading Indian pharmaceutical company specializing in the manufacture of active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients. Headquartered in Hyderabad, the company operates large-scale manufacturing facilities in Andhra Pradesh and Telangana, with a global footprint spanning over 100 countries. Established in 1990, Divis is known for its strong chemistries, process innovation, and focus on custom synthesis and contract manufacturing for major pharmaceutical companies worldwide.
The company maintains a concentrated focus on complex APIs, especially in therapies such as neurology, anti-inflammatories, antihistamines, and cardiovascular agents. Divis Laboratories consistently invests in research and development, in-house technology platforms, and green chemistry processes, which underpin its reputation for regulatory compliance with US FDA, EDQM, and other global agencies. Its diversified clientele includes major global pharma innovators and generic companies.
Business Model & Strategy
Divis Laboratories generates revenue mainly through the manufacture and export of generic APIs, advanced intermediates, and custom synthesis services. The company leverages fully integrated manufacturing sites, cost-efficient processes, and backward integration to maintain margins and supply reliability. Strategic growth drivers include expanding its product portfolio, deepening relationships with multinational pharma clients via long-term contracts, and sustained investments in capacity expansion and green chemistry.
Looking ahead, Divis is capitalizing on increasing global outsourcing, regulatory-driven supply chain diversification, and the shift from China by scaling custom manufacturing services and specialty APIs. The company continues to pursue innovation-led growth through R&D initiatives focused on niche molecules, chiral chemistry, and sustainable process improvements.
Management Overview
12 MembersMr.RAMESHBABU VENKATA NIMMAGADDA
Non-Executive - Independent Director-ChairpersonLKishoreBabu
Chief Financial OfficerMr.MURALI KRISHNA PRASAD DIVI
Executive Director-MDMr.NIMMAGADDA VENKATA RAMANA
Executive DirectorMr.SATCHANDRA KIRAN DIVI
Executive Director-CEOMs.NILIMA PRASAD DIVI
Executive DirectorMr.DEVENDRA RAO SUREDDY
Executive DirectorMr.GANAPATY SERU
Non-Executive - Independent DirectorMs.SUNAINA SINGH
Non-Executive - Independent DirectorMr.VEERAYYA CHOWDARY KOSARAJU
Non-Executive - Independent DirectorMr.RAJENDRA KUMAR PREMCHAND
Non-Executive - Independent DirectorMr.M. Satish Choudhury
Company Secretary & Compliance OfficerAwards & Recognition
5 Awards- Ranked among Top 3 Indian pharma API exporters (2024, Pharmexcil)
- Great Place to Work® Certified (2024-2025)
- CDP A- Rating for Environment (2024)
- 2024 CII Excellence Award for Sustainable Practices
- Continuous US FDA, EDQM, Japanese PMDA approvals (2024 audits)
Market Information
Company Timeline
35+ Years of Excellence | 10 Major Milestones
Founded by Dr. Murali K. Divi in Hyderabad, India
Commissioned first manufacturing plant at Choutuppal, Telangana
Listed on NSE and BSE after successful IPO
Entry into Custom Synthesis and Contract Manufacturing
Second major manufacturing facility operational at Vizag (Unit-II)
Commissioned new intermediate blocks in both units
Launched new nutraceuticals division
API manufacturing sites successfully cleared US FDA inspections
Capacity expansion for high-value specialty APIs completed
Announced strategic partnerships for global green chemistry initiatives
The Next Evolution
Contact Information
Registered Office
1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills, Gachibowli
Tel: 040-23786352 / 23786300 / 400,
Fax: 040-23786460,
Email: mail@divislaboratories.com; cs@divislaboratories.com
Website: divislabs.com
Corporate Actions
13| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹30 per share | 24 Jul 2026 Friday | 24 Jul 2026 Friday | - | - |
Final Dividend ₹30 per share | 25 Jul 2025 Friday | 25 Jul 2025 Friday | - | - |
Final Dividend ₹30 per share | 02 Aug 2024 Friday | 02 Aug 2024 Friday | - | - |
Final Dividend ₹30 per share | 11 Aug 2023 Friday | 11 Aug 2023 Friday | - | - |
Dividend ₹30 per share | 11 Aug 2022 Thursday | 12 Aug 2022 Friday | - | - |
Final Dividend ₹20 per share | 17 Aug 2021 Tuesday | - | 20 Aug 2021 Friday | 22 Aug 2021 Sunday |
Interim Dividend ₹16 per share | 25 Feb 2020 Tuesday | 26 Feb 2020 Wednesday | - | - |
Final Dividend ₹16 per share | 14 Aug 2019 Wednesday | - | 17 Aug 2019 Saturday | 23 Aug 2019 Friday |
Dividend ₹10 per share | 31 Aug 2018 Friday | - | 04 Sep 2018 Tuesday | 10 Sep 2018 Monday |
Dividend ₹10 per share | 15 Sep 2017 Friday | - | 19 Sep 2017 Tuesday | 25 Sep 2017 Monday |
Interim Dividend ₹10 per share | 17 Mar 2016 Thursday | 18 Mar 2016 Friday | - | - |
Bonus issue 1:1 | 23 Sep 2015 Wednesday | 26 Sep 2015 Saturday | - | - |
Dividend ₹20 per share | 06 Aug 2015 Thursday | - | 10 Aug 2015 Monday | 14 Aug 2015 Friday |
₹2,42,638 Cr.
₹9,165
₹9,467 / 5,637
81.21
₹631.37
14.48
₹112.55
₹2.00
0.33 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 5,102 | 5,584 | 7,032 | 9,074 | 8,112 | 8,184 | 9,712 | 11,067 | 11,682 |
| Expenses | - | - | - | 3,247 | 3,765 | 4,366 | 5,390 | 5,744 | 6,021 | 6,796 | 7,605 | 7,773 |
| Profit | - | - | - | 1,353 | 1,377 | 1,984 | 2,960 | 1,823 | 1,600 | 2,191 | 2,568 | 2,925 |
| Tax | - | - | - | 502 | 443 | 682 | 723 | 545 | 563 | 725 | 820 | 910 |
| EPS | - | - | - | 51 | 52 | 75 | 112 | 69 | 60 | 83 | 97 | 33.95 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 8,038 | 8,536 | 10,774 | 13,375 | 14,439 | 15,470 | 16,932 | 20,033 | - |
| Equity And Liabilities | - | - | - | 8,038 | 8,536 | 10,774 | 13,375 | 14,439 | 15,470 | 16,932 | 20,033 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 10 Apr '19 | Mar 2020 13 Apr '20 | Mar 2021 06 Apr '21 | Mar 2022 12 May '22 | Mar 2023 18 Apr '23 | Mar 2024 01 Jun '24 | Mar 2025 18 Apr '25 | Mar 2026 15 Apr '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 52.01% | 51.97% | 51.95% | 51.94% | 51.94% | 51.92% | 51.89% | 51.88% | - |
| Non Institutions | - | - | - | 12.56% | 13.35% | 11.45% | 11.28% | 12.31% | 11.19% | 9.39% | 8.60% | - |
| FII | - | - | - | - | - | - | - | 14.67% | 14.68% | 18.01% | 20.29% | - |
| DII | - | - | - | - | - | - | - | 21.07% | 22.21% | 20.71% | 19.22% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Divis Laboratories Ltd
Divis Laboratories Ltd
Divis Laboratories Ltd is a leading Indian pharmaceutical company specializing in the manufacture of active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients. Headquartered in Hyderabad, the company operates large-scale manufacturing facilities in Andhra Pradesh and Telangana, with a global footprint spanning over 100 countries. Established in 1990, Divis is known for its strong chemistries, process innovation, and focus on custom synthesis and contract manufacturing for major pharmaceutical companies worldwide.
The company maintains a concentrated focus on complex APIs, especially in therapies such as neurology, anti-inflammatories, antihistamines, and cardiovascular agents. Divis Laboratories consistently invests in research and development, in-house technology platforms, and green chemistry processes, which underpin its reputation for regulatory compliance with US FDA, EDQM, and other global agencies. Its diversified clientele includes major global pharma innovators and generic companies.
Divis Laboratories generates revenue mainly through the manufacture and export of generic APIs, advanced intermediates, and custom synthesis services. The company leverages fully integrated manufacturing sites, cost-efficient processes, and backward integration to maintain margins and supply reliability. Strategic growth drivers include expanding its product portfolio, deepening relationships with multinational pharma clients via long-term contracts, and sustained investments in capacity expansion and green chemistry.
Looking ahead, Divis is capitalizing on increasing global outsourcing, regulatory-driven supply chain diversification, and the shift from China by scaling custom manufacturing services and specialty APIs. The company continues to pursue innovation-led growth through R&D initiatives focused on niche molecules, chiral chemistry, and sustainable process improvements.
Ranked among Top 3 Indian pharma API exporters (2024, Pharmexcil)
Great Place to Work® Certified (2024-2025)
CDP A- Rating for Environment (2024)
2024 CII Excellence Award for Sustainable Practices
Continuous US FDA, EDQM, Japanese PMDA approvals (2024 audits)
Founded by Dr. Murali K. Divi in Hyderabad, India
Commissioned first manufacturing plant at Choutuppal, Telangana
Listed on NSE and BSE after successful IPO
Entry into Custom Synthesis and Contract Manufacturing
Second major manufacturing facility operational at Vizag (Unit-II)
Commissioned new intermediate blocks in both units
Launched new nutraceuticals division
API manufacturing sites successfully cleared US FDA inspections
Capacity expansion for high-value specialty APIs completed
Announced strategic partnerships for global green chemistry initiatives
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon